| Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors KH Lim, A Tefferi, TL Lasho, C Finke, M Patnaik, JH Butterfield, ... Blood, The Journal of the American Society of Hematology 113 (23), 5727-5736, 2009 | 655 | 2009 |
| GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts RM Sterner, R Sakemura, MJ Cox, N Yang, RH Khadka, CL Forsman, ... Blood, The Journal of the American Society of Hematology 133 (7), 697-709, 2019 | 545 | 2019 |
| Inherited antithrombin deficiency: a review MM Patnaik, S Moll Haemophilia 14 (6), 1229-1239, 2008 | 517 | 2008 |
| Eosinophilia: secondary, clonal and idiopathic A Tefferi, MM Patnaik, A Pardanani British journal of haematology 133 (5), 468-492, 2006 | 365 | 2006 |
| A pilot study of the telomerase inhibitor imetelstat for myelofibrosis A Tefferi, TL Lasho, KH Begna, MM Patnaik, DL Zblewski, CM Finke, ... New England Journal of Medicine 373 (10), 908-919, 2015 | 346 | 2015 |
| Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML A Tefferi, KH Lim, O Abdel-Wahab, TL Lasho, J Patel, MM Patnaik, ... Leukemia 23 (7), 1343-1345, 2009 | 320 | 2009 |
| Prospective, randomized, double-blind, phase III clinical trial of anti–T-lymphocyte globulin to assess impact on chronic graft-versus-host disease–free survival in patients … RJ Soiffer, HT Kim, J McGuirk, ME Horwitz, L Johnston, MM Patnaik, ... Journal of Clinical Oncology 35 (36), 4003-4011, 2017 | 291 | 2017 |
| ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients MM Patnaik, R Itzykson, TL Lasho, O Kosmider, CM Finke, CA Hanson, ... Leukemia 28 (11), 2206-2212, 2014 | 290 | 2014 |
| Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology JP Radich, M Deininger, CN Abboud, JK Altman, E Berman, R Bhatia, ... Journal of the National Comprehensive Cancer Network 16 (9), 1108-1135, 2018 | 256 | 2018 |
| SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value MM Patnaik, TL Lasho, JM Hodnefield, RA Knudson, RP Ketterling, ... Blood, The Journal of the American Society of Hematology 119 (2), 569-572, 2012 | 254 | 2012 |
| Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology MW Deininger, NP Shah, JK Altman, E Berman, R Bhatia, B Bhatnagar, ... Journal of the National Comprehensive Cancer Network 18 (10), 1385-1415, 2020 | 247 | 2020 |
| Myelodysplastic syndromes: contemporary review and how we treat N Gangat, MM Patnaik, A Tefferi American journal of hematology 91 (1), 76-89, 2016 | 245 | 2016 |
| Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes MM Patnaik, E Padron, RR LaBorde, TL Lasho, CM Finke, CA Hanson, ... Leukemia 27 (7), 1504-1510, 2013 | 233 | 2013 |
| SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival TL Lasho, T Jimma, CM Finke, M Patnaik, CA Hanson, RP Ketterling, ... Blood, The Journal of the American Society of Hematology 120 (20), 4168-4171, 2012 | 196 | 2012 |
| The Incidence and Severity of Oral Mucositis among AllogeneicáHematopoietic Stem Cell Transplantation Patients: A Systematic Review HM Chaudhry, AJ Bruce, RC Wolf, MR Litzow, WJ Hogan, MS Patnaik, ... Biology of blood and marrow transplantation 22 (4), 605-616, 2016 | 184 | 2016 |
| Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients MM Patnaik, CA Hanson, JM Hodnefield, TL Lasho, CM Finke, ... Leukemia 26 (1), 101-105, 2012 | 183 | 2012 |
| Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance MM Patnaik, TL Lasho, CM Finke, CA Hanson, JM Hodnefield, ... American journal of hematology 88 (3), 201-206, 2013 | 171 | 2013 |
| 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups N Szuber, M Mudireddy, M Nicolosi, D Penna, RR Vallapureddy, ... Mayo Clinic Proceedings 94 (4), 599-610, 2019 | 158 | 2019 |
| FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature A Pardanani, RP Ketterling, CY Li, MM Patnaik, AP Wolanskyj, MA Elliott, ... Leukemia research 30 (8), 965-970, 2006 | 158 | 2006 |
| Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a M ayo C linic‐F rench C onsortium S tudy EA Wassie, R Itzykson, TL Lasho, O Kosmider, CM Finke, CA Hanson, ... American journal of hematology 89 (12), 1111-1115, 2014 | 155 | 2014 |
Wilson I GonsalvesAssociate Professor of Medicine, Mayo Clinic, Rochester MNVerified email at mayo.edu
